Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 12/20 | 1.00 |
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24324927 | 0.85 | PLK1 (0.73) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL24324393 | 0.83 | PLK1 (1.00) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL24324227 | 0.80 | PLK1 (1.00) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL24324056 | 0.73 | PLK1 (0.64) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL24324204 | 0.70 | PLK1 (1.00) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL24324198 | 0.66 | PLK1 (1.00) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL29446363 | 0.65 | PLK1 (0.58) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL8649693 | 0.64 | PLK1 (0.52) | PLK1APOBEC3GGAANPC1SMN1; SMN2 | |
| SCHEMBL24324739 | 0.62 | PLK1 (0.74) | PLK1GAASMN1; SMN2TSHRUSP2 | |
| SCHEMBL11085909 | 0.62 | ALDH1A1 (0.84) | PLK1APOBEC3GGAANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216958-A2 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |